These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 29343314)
1. Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases. Celec P; Vlková B; Lauková L; Bábíčková J; Boor P Expert Rev Mol Med; 2018 Jan; 20():e1. PubMed ID: 29343314 [TBL] [Abstract][Full Text] [Related]
2. Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury. Oellerich M; Sherwood K; Keown P; Schütz E; Beck J; Stegbauer J; Rump LC; Walson PD Nat Rev Nephrol; 2021 Sep; 17(9):591-603. PubMed ID: 34031575 [TBL] [Abstract][Full Text] [Related]
3. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Song P; Wu LR; Yan YH; Zhang JX; Chu T; Kwong LN; Patel AA; Zhang DY Nat Biomed Eng; 2022 Mar; 6(3):232-245. PubMed ID: 35102279 [TBL] [Abstract][Full Text] [Related]
4. Simple and cost-effective laboratory methods to evaluate and validate cell-free DNA isolation. Mojtabanezhad Shariatpanahi A; Rokni P; Shahabi E; Varshoee Tabrizi F; Kerachian MA BMC Res Notes; 2018 Oct; 11(1):757. PubMed ID: 30352614 [TBL] [Abstract][Full Text] [Related]
5. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516 [TBL] [Abstract][Full Text] [Related]
6. Cell-Free DNA: Applications in Different Diseases. Ranucci R Methods Mol Biol; 2019; 1909():3-12. PubMed ID: 30580419 [TBL] [Abstract][Full Text] [Related]
7. Rapid detection of donor cell free DNA in lung transplant recipients with rejections using donor-recipient HLA mismatch. Zou J; Duffy B; Slade M; Young AL; Steward N; Hachem R; Mohanakumar T Hum Immunol; 2017 Apr; 78(4):342-349. PubMed ID: 28267558 [TBL] [Abstract][Full Text] [Related]
8. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing. Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539 [TBL] [Abstract][Full Text] [Related]
9. Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients. Grskovic M; Hiller DJ; Eubank LA; Sninsky JJ; Christopherson C; Collins JP; Thompson K; Song M; Wang YS; Ross D; Nelles MJ; Yee JP; Wilber JC; Crespo-Leiro MG; Scott SL; Woodward RN J Mol Diagn; 2016 Nov; 18(6):890-902. PubMed ID: 27727019 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review. Cervena K; Vodicka P; Vymetalkova V Mutat Res Rev Mutat Res; 2019; 781():100-129. PubMed ID: 31416571 [TBL] [Abstract][Full Text] [Related]
11. Liquid biopsies: DNA methylation analyses in circulating cell-free DNA. Zeng H; He B; Yi C; Peng J J Genet Genomics; 2018 Apr; 45(4):185-192. PubMed ID: 29706556 [TBL] [Abstract][Full Text] [Related]
12. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856 [TBL] [Abstract][Full Text] [Related]
13. The main sources of circulating cell-free DNA: Apoptosis, necrosis and active secretion. Hu Z; Chen H; Long Y; Li P; Gu Y Crit Rev Oncol Hematol; 2021 Jan; 157():103166. PubMed ID: 33254039 [TBL] [Abstract][Full Text] [Related]
14. Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases. Duvvuri B; Lood C Front Immunol; 2019; 10():502. PubMed ID: 30941136 [TBL] [Abstract][Full Text] [Related]
15. Donor-specific Cell-free DNA as a Biomarker in Solid Organ Transplantation. A Systematic Review. Knight SR; Thorne A; Lo Faro ML Transplantation; 2019 Feb; 103(2):273-283. PubMed ID: 30308576 [TBL] [Abstract][Full Text] [Related]
16. Preanalytical variables that affect the outcome of cell-free DNA measurements. Ungerer V; Bronkhorst AJ; Holdenrieder S Crit Rev Clin Lab Sci; 2020 Nov; 57(7):484-507. PubMed ID: 32393081 [TBL] [Abstract][Full Text] [Related]
17. Donor-specific circulating cell free DNA as a noninvasive biomarker of graft injury in heart transplantation. Macher HC; García-Fernández N; Adsuar-Gómez A; Porras-López M; González-Calle A; Noval-Padillo J; Guerrero JM; Molinero P; Borrego-Domínguez JM; Herruzo-Avilés Á; Rubio A Clin Chim Acta; 2019 Aug; 495():590-597. PubMed ID: 31175849 [TBL] [Abstract][Full Text] [Related]
18. Elevated levels of circulating cell-free DNA and neutrophil proteins are associated with neonatal sepsis and necrotizing enterocolitis in immature mice, pigs and infants. Nguyen DN; Stensballe A; Lai JC; Jiang P; Brunse A; Li Y; Sun J; Mallard C; Skeath T; Embleton ND; Berrington JE; Sangild PT Innate Immun; 2017 Aug; 23(6):524-536. PubMed ID: 28714327 [TBL] [Abstract][Full Text] [Related]
19. Characteristics, properties, and potential applications of circulating cell-free dna in clinical diagnostics: a focus on transplantation. Sherwood K; Weimer ET J Immunol Methods; 2018 Dec; 463():27-38. PubMed ID: 30267663 [TBL] [Abstract][Full Text] [Related]
20. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology. Ponti G; Manfredini M; Tomasi A Crit Rev Oncol Hematol; 2019 Sep; 141():36-42. PubMed ID: 31212145 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]